A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual
inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma
(PTCL).